Literature DB >> 29480322

[Differential indication for psychotherapy in psychosis : Are there evidence-based criteria?]

S Klingberg1, K Hesse2.   

Abstract

The major objective of this paper is to discuss the available evidence on the question as to which patients benefit most from psychotherapy in psychotic disorders and the question of which kind of psychotherapy. From a methodological perspective, this task can be seen as the question of moderators of treatment success. To answer this question, the status of efficacy research on psychotherapeutic interventions in schizophrenia is summarized in a first step. Secondly, studies comparing different active psychotherapeutic approaches are discussed. There are no studies available on routine psychotherapeutic care. However, there appears to be a rationale for recommending a combination of cognitive behavioural therapy (CBT) and family therapy. If patients prefer other approaches or if the treatment model does not suit the patient, other approaches should be offered. There is evidence for CBT that insight into psychosis, female gender, a higher level of education, and age >21 are indicators of a better course in CBT. Overall, the options for differential indications are highly limited and considerably more research is required.

Entities:  

Keywords:  Antipsychotics; Cognitive behavioral therapy; Family intervention; Psychoeducation; Schizophrenia

Mesh:

Year:  2018        PMID: 29480322     DOI: 10.1007/s00115-017-0474-0

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  25 in total

Review 1.  Mediators and moderators of treatment effects in randomized clinical trials.

Authors:  Helena Chmura Kraemer; G Terence Wilson; Christopher G Fairburn; W Stewart Agras
Journal:  Arch Gen Psychiatry       Date:  2002-10

2.  A meta-analysis of controlled research on social skills training for schizophrenia.

Authors:  Matthew M Kurtz; Kim T Mueser
Journal:  J Consult Clin Psychol       Date:  2008-06

3.  Patient Factors that Impact upon Cognitive Behavioural Therapy for Psychosis: Therapists' Perspectives.

Authors:  Siobhan Currell; Thomas Christodoulides; Jonna Siitarinen; Robert Dudley
Journal:  Behav Cogn Psychother       Date:  2015-06-25

Review 4.  Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias.

Authors:  S Jauhar; P J McKenna; J Radua; E Fung; R Salvador; K R Laws
Journal:  Br J Psychiatry       Date:  2014-01       Impact factor: 9.319

5.  Early intervention for relapse in schizophrenia: results of a 12-month randomized controlled trial of cognitive behavioural therapy.

Authors:  A Gumley; M O'Grady; L McNay; J Reilly; K Power; J Norrie
Journal:  Psychol Med       Date:  2003-04       Impact factor: 7.723

Review 6.  Family intervention for schizophrenia.

Authors:  Fiona Pharoah; Jair Mari; John Rathbone; Winson Wong
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08

7.  A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes.

Authors:  Til Wykes; Vyv Huddy; Caroline Cellard; Susan R McGurk; Pál Czobor
Journal:  Am J Psychiatry       Date:  2011-03-15       Impact factor: 18.112

8.  Psychoeducational psychotherapy for schizophrenic patients and their key relatives or care-givers: results of a 2-year follow-up.

Authors:  G Buchkremer; S Klingberg; R Holle; H Schulze Mönking; W P Hornung
Journal:  Acta Psychiatr Scand       Date:  1997-12       Impact factor: 6.392

9.  Family management in the prevention of exacerbations of schizophrenia: a controlled study.

Authors:  I R Falloon; J L Boyd; C W McGill; J Razani; H B Moss; A M Gilderman
Journal:  N Engl J Med       Date:  1982-06-17       Impact factor: 91.245

10.  Delusional belief flexibility and informal caregiving relationships in psychosis: a potential cognitive route for the protective effect of social support.

Authors:  S Jolley; H Ferner; P Bebbington; P Garety; G Dunn; D Freeman; D Fowler; E Kuipers
Journal:  Epidemiol Psychiatr Sci       Date:  2013-10-25       Impact factor: 6.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.